🏆 TechInvention recognized in Forbes India Select 200, featured among companies with Global Business Potential, reflecting the company's rapid growth and industry leadership.
We believe CSR must take an inclusive approach to all the stakeholders of the business to achieve our shared goal of bringing greater health equity through affordable, acceptable, and accessible healthcare for all.
TechInvention Lifecare limited, donated Rs 6 lakh to the BioNest-PU, one of North India’s top bio-incubators housed at Punjab University, Chandigarh, for research and development linked to the SARS-CoV2, at the onset of the COVID-19 pandemic.
TechInvention contributed to the PM Cares Fund, established by The Hon’ble Prime Minister of India in the wake of the COVID-19 pandemic, to carry out and support relief during a public health emergency, including the creation or upgrade of healthcare or pharmaceutical facilities, other necessary infrastructure, and also funding relevant research.
TechInvention inaugurated its BSL-2 R&D lab at the Regional Centre for Biotechnology's BSC BioNEST Bioincubator (RCB BBB) on December 6, 2022, in the presence of notable figures from the biotech industry and academia, as well as representatives from other start-ups.
Read ArticleTechInvention provided â‚ą15.95 lakh towards a 10-litre fermenter for the BSL-2 laboratory at the Regional Centre for Biotechnology, strengthening infrastructure for bioprocess development and vaccine research.
With financial support of â‚ą18.03 lakh, TechInvention backed research and development projects, education and training at the Regional Centre for Biotechnology and the Research Innovation Incubation Design Laboratory Foundation.
TechInvention extended ₹32.35 lakh to Ganpat University’s One Health Research Biotechnology Hub (GUNI-ORBIT) to support education and research. A further donation of ₹3.81 lakh to the PM CARES Fund brought its total support across these two years to ₹36.16 lakh.
Connect with us to explore collaborations, licensing partnerships, and capacity-building opportunities for vaccines and biotherapeutics globally.